UniProt ID | AJUBA_HUMAN | |
---|---|---|
UniProt AC | Q96IF1 | |
Protein Name | LIM domain-containing protein ajuba | |
Gene Name | AJUBA | |
Organism | Homo sapiens (Human). | |
Sequence Length | 538 | |
Subcellular Localization | Cytoplasm, cytoskeleton. Cell membrane. Cell junction. Nucleus. Cytoplasm, cytoskeleton, microtubule organizing center, centrosome. Cytoplasm, P-body. Shuttles between the cytoplasm and the nucleus. Localizes on centrosomes during G2-M phase. Prefere | |
Protein Description | Adapter or scaffold protein which participates in the assembly of numerous protein complexes and is involved in several cellular processes such as cell fate determination, cytoskeletal organization, repression of gene transcription, mitosis, cell-cell adhesion, cell differentiation, proliferation and migration. Contributes to the linking and/or strengthening of epithelia cell-cell junctions in part by linking adhesive receptors to the actin cytoskeleton. May be involved in signal transduction from cell adhesion sites to the nucleus. Plays an important role in regulation of the kinase activity of AURKA for mitotic commitment. Also a component of the IL-1 signaling pathway modulating IL-1-induced NFKB1 activation by influencing the assembly and activity of the PRKCZ-SQSTM1-TRAF6 multiprotein signaling complex. Functions as an HDAC-dependent corepressor for a subset of GFI1 target genes. Acts as a transcriptional corepressor for SNAI1 and SNAI2/SLUG-dependent repression of E-cadherin transcription. Acts as a hypoxic regulator by bridging an association between the prolyl hydroxylases and VHL enabling efficient degradation of HIF1A. Positively regulates microRNA (miRNA)-mediated gene silencing. Negatively regulates the Hippo signaling pathway and antagonizes phosphorylation of YAP1.. | |
Protein Sequence | MERLGEKASRLLEKFGRRKGESSRSGSDGTPGPGKGRLSGLGGPRKSGPRGATGGPGDEPLEPAREQGSLDAERNQRGSFEAPRYEGSFPAGPPPTRALPLPQSLPPDFRLEPTAPALSPRSSFASSSASDASKPSSPRGSLLLDGAGAGGAGGSRPCSNRTSGISMGYDQRHGSPLPAGPCLFGPPLAGAPAGYSPGGVPSAYPELHAALDRLYAQRPAGFGCQESRHSYPPALGSPGALAGAGVGAAGPLERRGAQPGRHSVTGYGDCAVGARYQDELTALLRLTVGTGGREAGARGEPSGIEPSGLEEPPGPFVPEAARARMREPEAREDYFGTCIKCNKGIYGQSNACQALDSLYHTQCFVCCSCGRTLRCKAFYSVNGSVYCEEDYLFSGFQEAAEKCCVCGHLILEKILQAMGKSYHPGCFRCIVCNKCLDGIPFTVDFSNQVYCVTDYHKNYAPKCAACGQPILPSEGCEDIVRVISMDRDYHFECYHCEDCRMQLSDEEGCCCFPLDGHLLCHGCHMQRLNARQPPANYI | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
|
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
7 | Methylation | -MERLGEKASRLLEK -CHHHHHHHHHHHHH | 50.27 | - | |
14 | Ubiquitination | KASRLLEKFGRRKGE HHHHHHHHHCCCCCC | 53.76 | 33845483 | |
30 | Phosphorylation | SRSGSDGTPGPGKGR CCCCCCCCCCCCCCC | 30.02 | 28985074 | |
39 | Phosphorylation | GPGKGRLSGLGGPRK CCCCCCCCCCCCCCC | 30.52 | 20068231 | |
53 | Phosphorylation | KSGPRGATGGPGDEP CCCCCCCCCCCCCCC | 45.56 | 28674419 | |
69 | Phosphorylation | EPAREQGSLDAERNQ HHHHHHCCCCCHHHH | 23.83 | 21815630 | |
79 | Phosphorylation | AERNQRGSFEAPRYE CHHHHCCCCCCCCCC | 23.31 | 21945579 | |
85 | Phosphorylation | GSFEAPRYEGSFPAG CCCCCCCCCCCCCCC | 24.47 | 21945579 | |
88 | Phosphorylation | EAPRYEGSFPAGPPP CCCCCCCCCCCCCCC | 19.00 | 21945579 | |
104 | Phosphorylation | RALPLPQSLPPDFRL CCCCCCCCCCCCCCC | 40.69 | 30266825 | |
114 | Phosphorylation | PDFRLEPTAPALSPR CCCCCCCCCCCCCCC | 35.58 | 29255136 | |
119 | Phosphorylation | EPTAPALSPRSSFAS CCCCCCCCCCHHCCC | 22.00 | 19664994 | |
122 | Phosphorylation | APALSPRSSFASSSA CCCCCCCHHCCCCCC | 32.94 | 23927012 | |
123 | Phosphorylation | PALSPRSSFASSSAS CCCCCCHHCCCCCCC | 26.55 | 23927012 | |
126 | Phosphorylation | SPRSSFASSSASDAS CCCHHCCCCCCCCCC | 23.86 | 23927012 | |
127 | Phosphorylation | PRSSFASSSASDASK CCHHCCCCCCCCCCC | 26.88 | 30278072 | |
128 | Phosphorylation | RSSFASSSASDASKP CHHCCCCCCCCCCCC | 29.33 | 23927012 | |
130 | Phosphorylation | SFASSSASDASKPSS HCCCCCCCCCCCCCC | 35.34 | 23927012 | |
133 | Phosphorylation | SSSASDASKPSSPRG CCCCCCCCCCCCCCC | 50.52 | 22167270 | |
136 | Phosphorylation | ASDASKPSSPRGSLL CCCCCCCCCCCCCEE | 57.63 | 22167270 | |
137 | Phosphorylation | SDASKPSSPRGSLLL CCCCCCCCCCCCEEE | 27.43 | 22167270 | |
141 | Phosphorylation | KPSSPRGSLLLDGAG CCCCCCCCEEECCCC | 19.68 | 30266825 | |
155 | Phosphorylation | GAGGAGGSRPCSNRT CCCCCCCCCCCCCCC | 31.93 | 30266825 | |
159 | Phosphorylation | AGGSRPCSNRTSGIS CCCCCCCCCCCCCCC | 31.84 | 30266825 | |
163 | Phosphorylation | RPCSNRTSGISMGYD CCCCCCCCCCCCCCC | 30.78 | 21815630 | |
166 | Phosphorylation | SNRTSGISMGYDQRH CCCCCCCCCCCCCCC | 15.07 | 27251275 | |
169 | Phosphorylation | TSGISMGYDQRHGSP CCCCCCCCCCCCCCC | 10.56 | 21552520 | |
175 | Phosphorylation | GYDQRHGSPLPAGPC CCCCCCCCCCCCCCC | 19.69 | 28731282 | |
195 | Phosphorylation | LAGAPAGYSPGGVPS CCCCCCCCCCCCCCC | 17.50 | 22199227 | |
196 | Phosphorylation | AGAPAGYSPGGVPSA CCCCCCCCCCCCCCH | 19.02 | 25394399 | |
202 | Phosphorylation | YSPGGVPSAYPELHA CCCCCCCCHHHHHHH | 37.72 | 27542207 | |
204 | Phosphorylation | PGGVPSAYPELHAAL CCCCCCHHHHHHHHH | 11.11 | 24211406 | |
215 | Phosphorylation | HAALDRLYAQRPAGF HHHHHHHHHCCCCCC | 11.11 | 28152594 | |
227 | Phosphorylation | AGFGCQESRHSYPPA CCCCCCCCCCCCCCC | 14.93 | 28152594 | |
230 | Phosphorylation | GCQESRHSYPPALGS CCCCCCCCCCCCCCC | 37.92 | 30266825 | |
231 | Phosphorylation | CQESRHSYPPALGSP CCCCCCCCCCCCCCC | 13.70 | 30266825 | |
237 | Phosphorylation | SYPPALGSPGALAGA CCCCCCCCCCHHCCC | 22.47 | 30266825 | |
263 | Phosphorylation | GAQPGRHSVTGYGDC CCCCCCCCCCCCCCC | 21.73 | 23927012 | |
265 | Phosphorylation | QPGRHSVTGYGDCAV CCCCCCCCCCCCCCC | 27.92 | 30266825 | |
267 | Phosphorylation | GRHSVTGYGDCAVGA CCCCCCCCCCCCCCC | 10.63 | 23927012 | |
276 | Phosphorylation | DCAVGARYQDELTAL CCCCCCHHHHHHHHH | 21.56 | 27642862 | |
340 | Ubiquitination | DYFGTCIKCNKGIYG CCCCCCEECCCCCCC | 33.62 | 29967540 | |
346 | Phosphorylation | IKCNKGIYGQSNACQ EECCCCCCCCCCHHH | 20.13 | - |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of AJUBA_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of AJUBA_HUMAN !! |
Interacting Protein | Gene Name | Interaction Type | PPI Reference | Domain-Domain Interactions |
---|---|---|---|---|
EAA2_HUMAN | SLC1A2 | physical | 11860269 | |
RARA_HUMAN | RARA | physical | 20133701 | |
RARG_HUMAN | RARG | physical | 20133701 | |
RXRG_HUMAN | RXRG | physical | 20133701 | |
ANM5_HUMAN | PRMT5 | physical | 18347060 | |
SNAI1_HUMAN | SNAI1 | physical | 18347060 | |
EGLN2_HUMAN | EGLN2 | physical | 22286099 | |
EGLN3_HUMAN | EGLN3 | physical | 22286099 | |
VHL_HUMAN | VHL | physical | 22286099 | |
BUB1B_HUMAN | BUB1B | physical | 18710370 | |
AURKB_HUMAN | AURKB | physical | 18710370 | |
LATS2_HUMAN | LATS2 | physical | 16413547 | |
LCK_HUMAN | LCK | physical | 15870274 | |
SQSTM_HUMAN | SQSTM1 | physical | 15870274 | |
KPCZ_HUMAN | PRKCZ | physical | 15870274 | |
TRAF6_HUMAN | TRAF6 | physical | 15870274 |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
There are no disease associations of PTM sites. | ||||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Phosphorylation | |
Reference | PubMed |
"Large-scale proteomics analysis of the human kinome."; Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,Mann M., Daub H.; Mol. Cell. Proteomics 8:1751-1764(2009). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-155 AND SER-159, ANDMASS SPECTROMETRY. | |
"A quantitative atlas of mitotic phosphorylation."; Dephoure N., Zhou C., Villen J., Beausoleil S.A., Bakalarski C.E.,Elledge S.J., Gygi S.P.; Proc. Natl. Acad. Sci. U.S.A. 105:10762-10767(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-119, AND MASSSPECTROMETRY. | |
"Kinase-selective enrichment enables quantitative phosphoproteomics ofthe kinome across the cell cycle."; Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,Greff Z., Keri G., Stemmann O., Mann M.; Mol. Cell 31:438-448(2008). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-119, AND MASSSPECTROMETRY. | |
"A probability-based approach for high-throughput proteinphosphorylation analysis and site localization."; Beausoleil S.A., Villen J., Gerber S.A., Rush J., Gygi S.P.; Nat. Biotechnol. 24:1285-1292(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-119, AND MASSSPECTROMETRY. | |
"Global, in vivo, and site-specific phosphorylation dynamics insignaling networks."; Olsen J.V., Blagoev B., Gnad F., Macek B., Kumar C., Mortensen P.,Mann M.; Cell 127:635-648(2006). Cited for: PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-263, AND MASSSPECTROMETRY. |